JP2019509976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509976A5 JP2019509976A5 JP2018528648A JP2018528648A JP2019509976A5 JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5 JP 2018528648 A JP2018528648 A JP 2018528648A JP 2018528648 A JP2018528648 A JP 2018528648A JP 2019509976 A5 JP2019509976 A5 JP 2019509976A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021163120A JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262303P | 2015-12-02 | 2015-12-02 | |
| US62/262,303 | 2015-12-02 | ||
| PCT/US2016/064394 WO2017096026A1 (en) | 2015-12-02 | 2016-12-01 | Antibodies specific to glycosylated pd-1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Division JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019509976A JP2019509976A (ja) | 2019-04-11 |
| JP2019509976A5 true JP2019509976A5 (https=) | 2020-01-16 |
| JP7003036B2 JP7003036B2 (ja) | 2022-02-04 |
Family
ID=58797717
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528648A Active JP7003036B2 (ja) | 2015-12-02 | 2016-12-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021163120A Active JP7455787B2 (ja) | 2015-12-02 | 2021-10-01 | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10858432B2 (https=) |
| EP (1) | EP3383412A4 (https=) |
| JP (2) | JP7003036B2 (https=) |
| KR (1) | KR102809728B1 (https=) |
| CN (1) | CN109152798B (https=) |
| WO (1) | WO2017096026A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| NZ739090A (en) | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| KR102809728B1 (ko) | 2015-12-02 | 2025-05-21 | 주식회사 에스티큐브 | 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법 |
| KR20180130541A (ko) * | 2016-03-29 | 2018-12-07 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법 |
| EP3487883B1 (en) | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| US20190343951A1 (en) * | 2017-01-13 | 2019-11-14 | National Research Council Of Canada | Method of optimizing peptide immuno-epitope by glycosylation, optimized peptide thereof and its use for conjugate vaccines |
| RU2761377C2 (ru) | 2017-04-03 | 2021-12-07 | Ф. Хоффманн-Ля Рош Аг | Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15 |
| TWI690538B (zh) | 2017-04-05 | 2020-04-11 | 瑞士商赫孚孟拉羅股份公司 | 特異性結合至pd1至lag3的雙特異性抗體 |
| US12215151B2 (en) | 2017-05-31 | 2025-02-04 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1 |
| CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
| AR114127A1 (es) | 2018-03-02 | 2020-07-22 | Lilly Co Eli | Anticuerpos agonistas contra pd-1 y usos de estos |
| EP3773916A4 (en) * | 2018-04-04 | 2021-12-15 | TrueBinding, Inc. | PROCEDURES AND COMPOSITIONS FOR BLOCKING THE INTERACTION BETWEEN NON-GLYCOSYLATED PD-1 POLYPEPTIDES |
| CN120714024A (zh) | 2018-06-20 | 2025-09-30 | 因赛特公司 | 抗pd-1抗体及其用途 |
| CN111166867B (zh) * | 2018-11-09 | 2022-12-20 | 中国科学院分子细胞科学卓越创新中心 | Pd-1泛素化激动剂的功能与用途 |
| CN111423510B (zh) * | 2019-01-10 | 2024-02-06 | 迈威(上海)生物科技股份有限公司 | 重组抗人pd-1抗体及其应用 |
| WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療 |
| EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
| CN114729045B (zh) * | 2019-09-26 | 2025-09-09 | 斯特库比公司 | 对糖基化的ctla-4特异性的抗体及其使用方法 |
| US12595304B2 (en) | 2019-10-09 | 2026-04-07 | Stcube & Co., Inc. | Antibodies specific to glycosylated LAG3 and methods of use thereof |
| WO2022068919A1 (zh) * | 2020-09-30 | 2022-04-07 | 正大天晴康方(上海)生物医药科技有限公司 | 结合pd-1抗体的肽及其应用 |
| KR20240005794A (ko) * | 2021-05-18 | 2024-01-12 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항 pd-1 폴리펩티드 및 그의 용도 |
| CN113372447A (zh) * | 2021-05-26 | 2021-09-10 | 重庆中元汇吉生物技术有限公司 | 抗pivka-ii单克隆抗体及其应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| CN1753912B (zh) * | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| EP1768999B1 (en) | 2004-06-30 | 2013-06-19 | Mayo Foundation For Medical Education And Research | sHIgM12 antibody useful to treat multiple sclerosis |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| HRP20131167T1 (hr) * | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009089149A1 (en) | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| WO2010098788A2 (en) * | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) * | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011109246A1 (en) | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| BR112014003315A2 (pt) | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| BR112014009962A2 (pt) | 2011-10-27 | 2019-09-24 | Nkt Therapeutics Inc | anticorpos humanizados para inkt |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN104411720B (zh) * | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| CA2886433C (en) | 2012-10-04 | 2022-01-04 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| EA034666B1 (ru) * | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| MY184154A (en) * | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095404A2 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| TWI681969B (zh) * | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CN103897036B (zh) * | 2014-03-24 | 2016-02-24 | 郑州大学 | 一种pd-1蛋白胞外段亲和肽l8及其应用 |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| CN107852765B (zh) | 2015-07-29 | 2022-03-08 | 夏普株式会社 | 用于设备到设备中继过程的方法 |
| NZ739090A (en) * | 2015-10-02 | 2025-06-27 | Hoffmann La Roche | Bispecific antibodies specific for pd1 and tim3 |
| CR20180151A (es) * | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Antcuierpos anti-pd1 y métodos de uso |
| KR102809728B1 (ko) * | 2015-12-02 | 2025-05-21 | 주식회사 에스티큐브 | 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법 |
-
2016
- 2016-12-01 KR KR1020187018671A patent/KR102809728B1/ko active Active
- 2016-12-01 US US15/778,663 patent/US10858432B2/en active Active
- 2016-12-01 JP JP2018528648A patent/JP7003036B2/ja active Active
- 2016-12-01 EP EP16871487.1A patent/EP3383412A4/en active Pending
- 2016-12-01 WO PCT/US2016/064394 patent/WO2017096026A1/en not_active Ceased
- 2016-12-01 CN CN201680078477.9A patent/CN109152798B/zh active Active
-
2020
- 2020-11-13 US US17/097,892 patent/US11981736B2/en active Active
-
2021
- 2021-10-01 JP JP2021163120A patent/JP7455787B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509976A5 (https=) | ||
| US12060423B2 (en) | Humanized, mouse or chimeric anti-CD47 monoclonal antibodies | |
| US10081680B2 (en) | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | |
| JP2019502405A5 (https=) | ||
| CA3043691C (en) | Antibody binding specifically to cd66c and use thereof | |
| JP2021512604A5 (https=) | ||
| JP2019512210A5 (https=) | ||
| JP7811028B2 (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| CN120958025A (zh) | 针对含cub结构域的蛋白1(cdcp1)的抗体及其用途 | |
| JPWO2022217019A5 (https=) | ||
| CA3177526C (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| TW202336033A (zh) | 抗體之新穎組合及用途 | |
| RU2022107092A (ru) | Новые анти-cldn18.2 антитела | |
| HK40040747A (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| JPWO2021072277A5 (https=) | ||
| JPWO2022242680A5 (https=) | ||
| HK1262017B (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies | |
| HK1262017A1 (en) | Humanized, mouse or chimeric anti-cd47 monoclonal antibodies |